Richard T. Davey
National Institutes of Health
National Institute of Allergy and Infectious Disease
Bethesda
MD 20892
USA
Name/email consistency: high
- Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy. Davey, R.T., Pertel, P.E., Benson, A., Cassell, D.J., Gazzard, B.G., Holodniy, M., Lalezari, J.P., Levy, Y., Mitsuyasu, R.T., Palella, F.J., Pollard, R.B., Rajagopalan, P., Saag, M.S., Salata, R.A., Sha, B.E., Choudhri, S. J. Interferon Cytokine Res. (2008)
- Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. Davey, R.T., Murphy, R.L., Graziano, F.M., Boswell, S.L., Pavia, A.T., Cancio, M., Nadler, J.P., Chaitt, D.G., Dewar, R.L., Sahner, D.K., Duliege, A.M., Capra, W.B., Leong, W.P., Giedlin, M.A., Lane, H.C., Kahn, J.O. JAMA (2000)
- HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Davey, R.T., Bhat, N., Yoder, C., Chun, T.W., Metcalf, J.A., Dewar, R., Natarajan, V., Lempicki, R.A., Adelsberger, J.W., Miller, K.D., Kovacs, J.A., Polis, M.A., Walker, R.E., Falloon, J., Masur, H., Gee, D., Baseler, M., Dimitrov, D.S., Fauci, A.S., Lane, H.C. Proc. Natl. Acad. Sci. U.S.A. (1999)
